BOSTON, MA - Ikena Oncology, Inc. (Nasdaq: IKNA), a leading targeted oncology company, has provided a significant organizational update, unveiling key objectives for advancing the development of its lead targeted oncology assets, IK-930 and IK-595. The company also announced a strategic organizational streamlining aimed at reallocating resources from exploratory research and discovery towards ongoing targeted oncology clinical programs. This move is part of Ikena's commitment to maximizing impact and propelling advancements in patient-directed cancer treatments.

Mark Manfredi, Ph.D., Chief Executive Officer of Ikena, emphasized the company's laser focus on advancing IK-930 and IK-595 in the coming year to yield interpretable and clear data reads, ultimately building value for investors. The streamlining effort includes a reduction in the workforce by approximately 35%, to be implemented throughout the first quarter of 2024.

"We are grateful for the impact our discovery and research team has had, but the renewed focus on our lead assets, IK-930 and IK-595, underscores our dedication to delivering the full therapeutic potential of our clinical candidates that we believe could transform the lives of cancer patients," stated Dr. Manfredi.

IK-930, a TEAD1-Selective Hippo Pathway Inhibitor, is making progress with an optimized formulation being dosed in the clinic alongside the original formulation. The company has expanded targeted recruitment of mesothelioma and epithelioid hemangioendothelioma (EHE) patients, with a clinical data update planned for the second half of 2024.

IK-595, a MEK-RAF Molecular Glue, has successfully passed the safety evaluation window for the initial cohort dosed in December 2023. Ongoing enrollment of targeted RAS and RAF mutant cancer patients in dose escalation is taking place, exploring multiple dosing schedules. Backfill and expansion cohorts are also planned in multiple indications where IK-595 may have differentiated advantages.

The strategic decision to reallocate resources from the discovery organization to clinical programs has been driven by the significant progress of IK-930 and IK-595. This includes a reduction in the workforce to enhance operational efficiency. With approximately $175 million in cash and cash equivalents as of December 31, 2023 (unaudited), the company's runway is extended into the second half of 2026.

Ikena Oncology, with a focus on developing differentiated therapies targeting nodes of cancer growth, spread, and therapeutic resistance, aims to efficiently develop innovative drugs for patients in need. The company's commitment to advancing its lead programs while optimizing its organizational structure reflects its dedication to addressing critical challenges in cancer treatment.

PHILADELPHIA, PA –– Darshan Shawn Parekh, PharmD, MHA, FACHE, has been appointed Chief Executive Officer of Roxborough Memorial Hospital, succeeding Burton Piper, who moved back to Tennessee to be closer to his family.

Parekh brings more than 20 years of acute care hospital management experience to his new position. He has extensive experience in growing and expanding programs, services, and facilities. Most recently, he served as Vice President at Temple University Health System, where he was responsible for oversight and provision of all pharmaceutical services within the health system. Prior to that role, Parekh was Vice President and Chief Ancillary Officer for Prospect Medical Holdings, a for-profit health system in California. Earlier in his career, he held pharmacy leadership positions with Jefferson Health in Abington, PA; the Massachusetts State Office of Pharmacy Services in Tewksbury, MA; Robert Wood Johnson University Hospital in Rahway, NJ; and Merck Research Laboratories.

“We are thrilled to have Shawn join Roxborough Memorial Hospital as the next CEO and member of the Senior Leadership Team,” said Sonia Mehta, MD, Chief Executive Officer, Region II, Corporate Chief Medical Officer, and Chief Academic Officer, Prime Healthcare Services. “Shawn’s acumen and accomplishments in safety, clinical excellence, quality, and performance metrics in operations and designing strategies have resulted in better patient care and outcomes, while enabling growth consistent with an organization’s core mission.”

“I am delighted to be joining Roxborough Memorial Hospital. This is an outstanding opportunity to be part an organization with a strong commitment to medical excellence,” said Parekh. “I look forward to working collaboratively with our medical staff, employees, patients, and the community to improve lives and to build a healthier tomorrow.”

Parekh earned his Master of Healthcare Administration from Ohio University in Athens, OH, and a Doctor of Pharmacy from the University of the Sciences in Philadelphia. Throughout his career, he has served on numerous boards and committees, and he is also a Fellow of the American College of Healthcare Executives.

Roxborough Memorial Hospital is an award-winning 131-bed acute care and teaching community hospital, in Philadelphia. It is part of Prime Healthcare Services, headquartered in Ontario, California, one of the nation’s leading hospital systems that also operates Suburban Community Hospital in Norristown, PA and Lower Bucks Hospital in Bristol, PA.

Roxborough Memorial has consistently received a Healthgrades Patient Safety Excellence Award and the American Heart Association/American Stroke Association’s Stroke Silver Plus Quality Award. It has been home to the Roxborough School of Nursing since 1898, as well as respected academic programs and medical staff.

BOSTON, MA - Clearway Health, a specialty pharmacy accelerator partnering with hospitals and health systems, has pioneered a model to support hospitals in enabling access to novel gene therapy treatments. The model was used to execute and accelerate payor, legal and procurement processes for Children’s National Hospital in Washington, D.C., to treat their first pediatric patient with ZYNTEGLO^®, a one-time, potentially curative breakthrough gene therapy treatment for transfusion-dependent beta-thalassemia, a rare blood disorder requiring regular red blood cell transfusions.

“Novel gene therapies represent the advancement of emerging therapies addressing the possibility of untethering patients from a lifetime of burdensome, costly, chronic care with a single treatment. While very promising, the full clinical impact of these treatments is not yet clear, driving questions on coverage, cost efficiency and delivery,” said Shawn Francis, PharmD, director of specialty pharmacy at Clearway Health.

By 2030, 54 approved gene and cell therapies are expected in the FDA pipeline, making it essential for healthcare institutions to adequately prepare to deliver gene therapy.

Navigating a potentially multimillion-dollar drug therapy involves a multidisciplinary approach that can be extremely time intensive and costly for health systems, involving an understanding of payor dynamics, prior authorizations, geographic complexities, patient financial access, assessment of proper staff training, legal and risk management, orchestration of stakeholders  and determining a procurement pathway. Clearway Health’s innovative framework supports health systems in navigating these dynamics, as well as the various intricacies that make it possible to absorb the high costs of a one-time, lump sum payment while protecting the financial integrity of the institution.

“Many health systems are not set up to coordinate the procurement of a novel gene therapy. There are an incredible amount of steps and considerations involved in the process,” said Eric Manuel Balmir, BS, MS, PharmD, CIM, vice president of clinical ancillary services and chief pharmacy officer of Children’s National Hospital. “Clearway Health’s framework allowed us to quickly and efficiently address these concerns, positioning our hospital to provide the latest pharmaceutical advancement.”

FORT LAUDERDALE, FL - Broward Health Medical Center's pharmacy program recently earned URAC Specialty Pharmacy Accreditation. This significant accomplishment demonstrates the hospital's success in setting high standards for outpatient pharmacies.

"This accreditation reflects the tremendous dedication of the pharmacy team, which strives to provide outstanding service to our South Florida community," said Manny Linares, CEO of Broward Health Medical Center. “After three years of hard work, we are delighted to have achieved the accreditation.”

URAC is the independent leader in promoting healthcare quality by setting high standards for clinical practice, consumer protections, performance measurement, operations infrastructure, and risk management. Broward Health's flagship hospital has successfully demonstrated its commitment to quality care, enhanced processes, patient safety, and improved outcomes.

“We are incredibly proud to have achieved this accreditation,” said Dave Lacknauth, PharmD, executive director of pharmacy services at Broward Health. “We understand the importance of these specialty medications in our community and are committed to delivering quality standards of care.”

“Now more than ever, specialty pharmacies are an essential part of the patient care team and patient experience. URAC congratulates Broward Health Medical Center on its achievement of Specialty Pharmacy Accreditation. This achievement demonstrates excellence in pharmacy operations, product handling, patient education, and patient management. When an organization achieves URAC accreditation, it demonstrates a commitment to improving the quality of care, which is important to patients, providers and payers,” said URAC’s President and CEO Shawn Griffin, M.D.

DAVOS, Switzerland - The world faces an emergency in women’s health even as the COVID-19 pandemic wanes, according to one of the largest annual updates on women’s well-being — the Hologic Global Women’s Health Index.

Women’s health innovation company Hologic, Inc. (Nasdaq: HOLX) partners with Gallup to create the Index, which in its third year shows that billions of women are not getting tested for potentially life-threatening conditions. The Index also shows that more women are sad, angry and worried now than at the height of the pandemic. Many young women don’t feel safe walking alone in their communities at night, and nearly 1 billion women spend a lot of their day in physical pain.

This year’s Index will be released today at the World Economic Forum in Davos, Switzerland. The launch event was convened by Goals House, a community that comes together at significant global moments throughout the year to drive progress toward the United Nations (UN) Sustainable Development Goals (SDGs).

The Index fills a critical gap in knowledge about the health, safety and well-being of women worldwide. Based on interviews with more than 147,000 women and men in 143 countries and territories, it represents the voices of 97% of the world’s women and girls aged 15 and older.

“The new Index findings make it exceedingly evident that, as countries emerge from the COVID-19 pandemic, women’s health remains in a state of emergency,” said Stephen P. MacMillan, Chairman, President and CEO of Hologic. “It’s time for world leaders to take a bolder stand for women and girls. Investing in women’s health not only benefits individual women, but also their families, communities and economies.”

Key findings from this year’s Index:

• Testing for major health conditions remains low. Most women didn’t receive key tests in the past 12 months, meaning that billions of women went untested for potentially life-threatening conditions:
  • Only 36% were tested for high blood pressure — a major risk factor for heart disease and stroke.
  • 19% were tested for diabetes, a leading cause of death for women.
  • 11% were tested for any type of cancer.
  • 10% were tested for a sexually transmitted disease or infection (STD/STI) — leaving nearly 2 billion women of reproductive age at risk of infertility, increased maternal and fetal mortality, and deadly diseases.
• Emotional health is worsening: More women say they are sad, angry and worried now than three years ago. About 4 in 10 women experienced worry and stress during a lot of the previous day, and women are more likely than men to report feeling these emotions. For example, women are 20% more likely than men to say they experience sadness daily.
• Other striking findings:
  • Physical pain is a significant problem. Nearly 1 billion women worldwide spent a lot of the previous day in physical pain.
  • Housing challenges continue. The percentage of women struggling to afford shelter has increased by more than half in the last decade.
  • Young women don’t feel safe. Many women, including more than 4 in 10 young women aged 15 to 24, do not feel safe walking alone at night.

Based on survey responses, the Index assigns a women’s health score to each country or territory. Taiwan led the world for the third consecutive year, scoring 72 out of a possible 100. Other top scores went to Kuwait (68), Austria (67) and Germany (67). The lowest scores went to the Democratic Republic of Congo (36), Sierra Leone (34) and Afghanistan (26).

The United States fell seven places from its ranking in the second year of the survey to number 30, on par with Kazakhstan. The United Kingdom and France both scored 60, a few points above the global average.

“The Index serves as a wake-up call that improving women’s health needs to be a top priority. If we follow the roadmap set out in this Index, we can meaningfully improve the health and well-being of women for generations to come,” said MacMillan.

This year’s Index report includes country spotlights, including case studies on what is working well. South Korea is a consistent leader in cancer testing, and after recent prioritization, Costa Rica is among the top countries for blood pressure testing.

To see the full Index and related resources, visit WomensHealthIndex.com.

RAHWAY, NJ - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) for the treatment of patients with FIGO (International Federation of Gynecology and Obstetrics) 2014 Stage III-IVA cervical cancer. The approval is based on data from the Phase 3 KEYNOTE-A18 trial, in which KEYTRUDA plus CRT demonstrated an improvement in progression-free survival (PFS), reducing the risk of disease progression or death by 41% (HR=0.59 [95% CI, 0.43-0.82]) compared to placebo plus CRT in patients with FIGO 2014 Stage III-IVA disease. Median PFS was not reached in either group. This approval marks the third indication for KEYTRUDA in cervical cancer and the 39^th indication for KEYTRUDA in the U.S.

“Today’s approval of KEYTRUDA plus chemoradiotherapy is welcome news and gives patients with newly diagnosed FIGO 2014 Stage III-IVA cervical cancer, for the first time ever, the option of an anti-PD-1-based regimen to treat their cancer,” said Dr. Bradley Monk, oncologist and professor of obstetrics and gynecology at University of Arizona’s College of Medicine and Creighton University School of Medicine. “This KEYTRUDA-based regimen offers a new treatment option for these patients, so today’s approval has important implications for the way we treat them moving forward.”

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and can affect more than one body system simultaneously. Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions. Early identification and management of immune-mediated adverse reactions are essential to ensure safe use of KEYTRUDA. Based on the severity of the adverse reaction, KEYTRUDA should be withheld or permanently discontinued and corticosteroids administered if appropriate. KEYTRUDA can also cause severe or life-threatening infusion-related reactions. Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman. For more information, see “Selected Important Safety Information” below.

“Building on the established role of KEYTRUDA in advanced cervical cancer, KEYTRUDA plus chemoradiotherapy is now the first anti-PD-1-based regimen approved in the U.S. for the treatment of patients with FIGO 2014 Stage III-IVA cervical cancer regardless of PD-L1 expression,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. “This approval provides newly diagnosed patients with an anti-PD-1-based treatment option that has the potential to reduce the risk of disease progression or death compared to chemoradiotherapy alone.”

In the U.S., KEYTRUDA has two additional approved indications in cervical cancer: in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (Combined Positive Score [CPS] ≥1) as determined by an FDA-approved test; and as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test.

Study design and additional data supporting the approval

KEYNOTE-A18, also known as ENGOT-cx11/GOG-3047, is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial (ClinicalTrials.gov, NCT04221945) sponsored by Merck and conducted in collaboration with the European Network for Gynaecological Oncological Trial (ENGOT) groups and the GOG Foundation, Inc. (GOG) investigating KEYTRUDA in combination with CRT (cisplatin and external beam radiotherapy [EBRT] followed by brachytherapy [BT]). The trial enrolled 1,060 patients with cervical cancer who had not previously received any definitive surgery, radiation, or systemic therapy for cervical cancer. There were 596 patients with FIGO 2014 Stage III-IVA cervical cancer (tumor involvement of the lower vagina with or without extension onto pelvic sidewall or hydronephrosis/non-functioning kidney or has spread to adjacent pelvic organs) with either node-positive or node-negative disease, and 462 patients with FIGO 2014 Stage IB2-IIB cervical cancer (tumor lesions >4 cm or clinically visible lesions that have spread beyond the uterus but have not extended onto the pelvic wall or to the lower third of vagina) with node-positive disease; two patients had FIGO 2014 Stage IVB disease. Patients were randomized (1:1) to receive either:

• KEYTRUDA (200 mg intravenously [IV]) every three weeks (Q3W) for five cycles concurrent with cisplatin (40 mg/m² IV) weekly for five cycles (an optional sixth infusion could be administered per local practice) and radiotherapy (EBRT followed by BT), followed by KEYTRUDA (400 mg IV) every six weeks (Q6W) for 15 cycles;
• Placebo IV Q3W for five cycles concurrent with cisplatin (40 mg/m² IV) weekly for five cycles (an optional sixth infusion could be administered per local practice) and radiotherapy (EBRT followed by BT), followed by placebo IV Q6W for 15 cycles.

Treatment continued until RECIST v.1.1-defined progression of disease as determined by investigator or unacceptable toxicity. Assessment of tumor status was performed every 12 weeks from completion of CRT for the first two years, followed by every 24 weeks in year three, and then annually. The major efficacy outcome measures were PFS as assessed by investigator according to RECIST v1.1, modified to follow a maximum of 10 target lesions and a maximum of five target lesions per organ, or histopathologic confirmation, and overall survival (OS).

The trial demonstrated a statistically significant improvement in PFS in the overall population. In an exploratory subgroup analysis for the 462 patients (44%) with FIGO 2014 Stage IB2-IIB disease, the PFS HR estimate was 0.91 (95% CI, 0.63-1.31), indicating that the PFS improvement in the overall population was primarily attributed to the results seen in the subgroup of patients with FIGO 2014 Stage III-IVA disease. Overall survival data were not mature at the time of PFS analysis, with 10% deaths in the overall population.

In the exploratory subgroup analysis of 596 patients with FIGO 2014 Stage III-IVA disease, 61 patients (21%) in the KEYTRUDA plus CRT arm (n=293) experienced a PFS event versus 94 patients (31%) in the placebo plus CRT arm (n=303). Median PFS was not reached in either arm. The 12-month PFS rate was 81% (95% CI, 75-85) for KEYTRUDA plus CRT versus 70% (95% CI, 64-76) for placebo plus CRT.

The median duration of exposure to KEYTRUDA was 12.1 months (range, 1 day to 27 months). Fatal adverse reactions occurred in 1.4% of 292 patients receiving KEYTRUDA in combination with chemoradiotherapy, including one case each (0.3%) of large intestinal perforation, urosepsis, sepsis, and vaginal hemorrhage. Serious adverse reactions occurred in 30% of patients receiving KEYTRUDA in combination with CRT. Serious adverse reactions occurred in 30% of patients receiving KEYTRUDA in combination with CRT. Serious adverse reactions occurring in ≥1% of patients included urinary tract infection (2.7%), urosepsis (1.4%), and sepsis (1%). KEYTRUDA was discontinued for adverse reactions in 7% of patients. The most common adverse reaction (≥1%) resulting in permanent discontinuation was diarrhea (1%). Adverse reactions leading to interruption of KEYTRUDA occurred in 43% of patients; the most common adverse reactions leading to interruption of KEYTRUDA (≥2%) were anemia (8%), COVID-19 (6%), SARS-CoV-2 test positive (3.1%), decreased neutrophil count (2.7%), diarrhea (2.7%), urinary tract infection (2.7%), and increased alanine aminotransferase (2.4%). The most common adverse reactions (≥10%) among patients receiving KEYTRUDA were nausea (56%), diarrhea (50%), vomiting (33%), urinary tract infection (32%), fatigue (26%), hypothyroidism (20%), constipation (18%), decreased appetite and weight loss (17% each), abdominal pain and pyrexia (12% each), hyperthyroidism, dysuria and rash (11% each), and pelvic pain (10%).

On Thursday, Ballad health system unveiled three Omnicell XR2 Central Pharmacy Dispensing robots at Bristol Regional Medical Center to enhance the operations of its pharmacy services. The robots are part of a central pharmacy dispensing system that improves safety, workflow and inventory optimization through automation, enabling pharmacy team members to focus on other aspects of care.

"The introduction of Omnicell XR2 robots for our Pharmacy Central Fill Services at Bristol Regional marks a transformative moment in our commitment to patient well-being,” said Marvin Eichorn, chief administrative officer for Ballad Health. “This leading-edge technology will not only streamline our medication management processes, but it is also designed to contribute to enhanced patient safety and cost-effectiveness."

The Omnicell XR2 robots are intended to bring a host of benefits to Ballad Health’s Pharmacy Central Fill Services and the entire health system, including:

· Decreasing the manual handling of medications by technicians and pharmacists

· Reducing expired medication waste by dispensing earliest-to-expire and optimizing inventory across Ballad Health

· Providing complete, real-time visibility to every dose and its expiration date

· Enhancing patient safety by leveraging 100% barcode scanning

"The Omnicell XR2 automation represents a significant leap forward for our Pharmacy Central Fill Services,” said Trish Tanner, chief pharmacy officer at Ballad Health. “With fewer touchpoints, these state-of-the-art robots will empower our team members to redirect their focus towards more clinical initiatives, ultimately enhancing the overall quality of patient care."

The selection of Bristol Regional to receive the Omnicell XR2 robots was based on several factors, with its central location in the Appalachian Highlands and proximity to the entire Ballad Health service area playing a crucial role. This positioning ensures Pharmacy Central Fill Services at Bristol Regional will be within a reasonable courier distance for all Ballad Health hospitals, facilitating swift and efficient medication distribution.

In a unique and creative approach to integrating the outcomes-driven technology into the workflow, Ballad Health invited team members to participate in naming the XR2 robots.

Given Bristol's rich musical heritage, particularly the 1927 Bristol Sessions that ignited the country music movement across America and the Birthplace of Country Music Museum, the theme chosen for the robots’ name and decal design is country music. Following a survey among team members, the selected names for the three XR2 robots pay homage to iconic singer-songwriters Dolly Parton, Johnny Cash and June Carter-Cash.

As Ballad Health prepared to launch the technology at Bristol Regional, they celebrated the impact the Omnicell XR2 robots are anticipated to have on patient care and operational efficiency during a team member event, where the robots’ names were also unveiled.

“By leveraging advanced technology, these robots will not only streamline our medication management processes, but are also designed to significantly enhance patient safety,” Tanner said.

“The expected reduction in medication errors, improved inventory management and increased focus on clinical initiatives should collectively contribute to a healthcare environment that is safer, more efficient and ultimately more patient-centric. We believe that embracing innovation in this manner aligns with our commitment to providing the highest standard of care for our patients across Ballad Health."

More information about the services and hospitals of Ballad Health is available at www.balladhealth.org.

FORT WORTH, TX - Omnicell, Inc. (Nasdaq: OMCL) (“Omnicell” or the “Company”), a leader in transforming the pharmacy care delivery model, today announced that the Board of Directors elected Eileen Voynick to the Board, effective January 5, 2024. Ms. Voynick fills the vacancy resulting from Sara J. White, a Class I director who stepped down from the Company’s Board of Directors, effective January 5, 2024. In addition, the Company announced that Vance Moore will not stand for reelection to the Company’s Board at Omnicell’s 2024 annual meeting of stockholders (the “2024 annual meeting”) and effective as of the 2024 annual meeting, the size of the Board will be reduced from ten to nine directors.

Ms. Voynick brings over three decades of experience driving sales and operations at global industry leaders, including in the healthcare technology industry, at the executive and board level. She most recently served as Chief Executive Officer of Sparta Systems Inc., a leading provider of enterprise-quality management software solutions. Prior to Sparta Systems, Ms. Voynick served as Chief Operating Officer at Allscripts Healthcare Solutions, Inc. (n/k/a Veradigm Inc., Nasdaq: MDRX), as Executive Vice President of global sales, services, and support at Misys Healthcare Systems, and in various management positions at Oracle, SAP, Siebel Systems, Gartner, Ariba, and Accenture. Ms. Voynick is currently board chair of AGS Health LLC, a revenue cycle management provider, and has held board positions for several other organizations, including Skydeck Acquisition Corp. (former Nasdaq: SKYAU), CDK Global, Inc. (former Nasdaq: CDK), r3, Advanced MD Health, Jefferson Health, Philadelphia University and Thomas Jefferson University.

“We are pleased to welcome Eileen to the Omnicell Board of Directors,” said Randall Lipps, chairman, president, chief executive officer, and founder of Omnicell. “Eileen is a widely respected leader with significant experience in the software, technology, and healthcare industries, as well as a proven track record creating value for stockholders, accelerating growth, driving operational excellence, and developing global businesses. I am confident that her skills will complement and strengthen our Board as Omnicell continues to focus on driving long-term value and delivering outcome-centric innovations to improve patient outcomes.”

Mr. Lipps continued, “I would like to thank Sara and Vance for their dedication and outstanding contributions to the Board. Over the years, they have provided valuable insights and counsel to support Omnicell in furthering our strategy.”

“Omnicell is at the forefront of delivering mission-critical medication management solutions, and I am honored to join the Board,” said Ms. Voynick. “As hospitals and health systems are relying on technology now more than ever to serve patients, I look forward to leveraging my background in software, healthcare, and operations and working alongside Randall and the rest of the Board as we continue to further our innovation agenda for the benefit of our customers and enhance stockholder value.”

Ms. Voynick has been appointed to the Board’s Corporate Governance Committee. Following the 2024 annual meeting, the Omnicell Board will be comprised of nine directors, eight of whom are independent, and all of whom bring a broad range of expertise and skills necessary to oversee and direct the Company’s business. Six of those independent directors have been added to the Board in the last four years.

About Omnicell

Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.

OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.

GAITHERSBURG, MD - Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has secured an indefinite-delivery, indefinite-quantity (IDIQ) procurement contract with a maximum value up to $235.8 million to supply BioThrax® (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease. The new contract with the U.S. Department of Defense (DoD) and led by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, is comprised of a five-year base agreement ending on September 30, 2028, and an additional five-year option that would extend the contract to September 30, 2033. 

“As a part of our mission to protect and enhance lives, Emergent is proud to continue supporting and preparing our nation’s service members who have a high risk of exposure to anthrax bacteria by supplying BioThrax vaccine,” said Paul Williams, senior vice president, products head at Emergent. “This new contract award is a testament to the importance of Emergent’s medical countermeasures portfolio, and we look forward to delivering on our commitments to the U.S. DoD.” 

Under the initial five-year IDIQ contract, there is a guaranteed purchase minimum of $20.1 million, with future orders estimated to be at least $20 million for each following year for a total award value up to $235.8 million.